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Abstract
Background Public drug plans are faced with increasingly
difficult funding decisions. In Canada, the pan-Canadian
Oncology Drug Review (pCODR) makes funding recom-
mendations to the provincial and territorial drug plans
responsible for cancer drugs. Assessments of the economic
models submitted by pharmaceutical manufacturers are
publicly reported.
Objectives The main objective of this research was to
identify recurring methodological issues in economic
models submitted to pCODR for funding reviews. The
secondary objective was to explore whether there exists
any observed relationships between reported methodolog-
ical issues and funding recommendations made by
pCODR’s expert review committee.
Methods Publicly available Economic Guidance Reports
from July 2011 (inception) until June 2014 for drug
reviews with a final funding recommendation (N = 34)
were independently examined by two authors. Major
methodological issues from each review were abstracted
and grouped into nine main categories. Each issue was also
categorized based on perception of the reviewer’s actions
to manage it.
Results The most commonly reported issues involved
costing (59% of reviews), time horizon (56%), and model
structure (36%). Several types of issues were identified that
usually could not be resolved, such as quality of clinical
data or uncertainty with indirect comparisons. Issues with
costing or choice of utility estimates could usually be
addressed or explored by reviewers. No statistically sig-
nificant relationship was found between any methodologi-
cal issue and funding recommendations from the expert
review committee.
Conclusions The findings provide insights that can be used
by parties who submit or review economic evidence for
continuous improvement and consistency in economic
modeling, reporting, and decision making.
Key Points for Decision Makers
The most frequently reported issues found in the
pan-Canadian Oncology Drug Review (pCODR)
reports were related to costing, time horizon, and
model structure.
While not statistically significant, there appears to be
a trend between time horizon and model structure
and funding recommendations.
The results of this research suggest areas in which to
focus efforts to improve economic submissions.
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In Canada, it is estimated that 6.7% of healthcare budgets
are spent on cancer care [1]. Expenditures on oncology
drugs account for a large proportion of healthcare spend-
ing, and this trend is expected to increase, due in part to the
rapid introduction of costly new treatments and increase in
cancer incidence as the population ages [2]. Approximately
149 distinct cancer drugs are expected to come to market in
the next 5 years [3]. As healthcare budgets are limited,
public drug plans are faced with increasingly difficult
choices around which drugs to fund and under what cir-
cumstances to fund them. An economic evaluation that
compares both the costs and effects of a new drug com-
pared with the current standard of care can be one tool to
inform decision makers when making difficult funding
decisions.
There are major complexities in assessing cancer drugs.
The clinical evidence is often based on surrogate outcomes.
Drugs are commonly life-extending rather than curative,
and are usually very costly [4]. These factors often result in
oncology drugs exceeding common thresholds for cost
effectiveness [2, 4]. Canada has a funding review process
specifically for oncology drugs [5–7]. The intent of a for-
mal funding review process is to apply high quality and
consistent evaluation methods to generate recommenda-
tions [8].
The pan-Canadian Oncology Drug Review (pCODR)
was established in 2011 to assess new oncology drugs and/
or new clinical indications and make evidence-based rec-
ommendations to the Canadian provincial and territorial
drug plans (excluding Quebec) [5]. Pharmaceutical manu-
facturers (i.e., submitters) provide submissions to pCODR
on the clinical evidence, cost effectiveness, and budget
impact of the new drug. Submitters are to follow the
Canadian Agency for Drugs and Technologies in Health
guidelines for the economic evaluation of health tech-
nologies that are specific to oncology products [9]. The
pCODR recommendations are based on a deliberative
framework that considers clinical benefit, economic eval-
uation, adoption feasibility, and patient values [5]. The
pCODR Expert Review Committee (pERC) is a multidis-
ciplinary group that considers all the evidence and makes a
funding recommendation. Economic reviewers are engaged
in the review process to provide an assessment of a sub-
mitted economic evaluation model and detail any modifi-
cations and critiques of the model in an economic guidance
report, a summary of which is made publicly available on
the agency’s website (http://www.cadth.ca/pcodr). Eco-
nomic reviewers are selected by pCODR and assigned
submissions. Economic reviewers engage with the sub-
mitters at the midpoint of a review to clarify any details
and request additional analysis, as needed, as well as
receive the submitter’s feedback on the initial recommen-
dation before the final guidance and recommendation are
posted [10]. Any drug recommended by pCODR is then
considered for reimbursement and pricing negotiation by
the individual provinces and territories, or through the pan-
Canadian Pharmaceutical Alliance, which combines the
purchasing power of provincial and territorial drug plans.
Few studies have been published identifying issues in
economic evaluations submitted to health technology
assessment (HTA) bodies worldwide [11–17]. One study
conducted in Canada prior to the establishment of pCODR
found that the most common limitations of submitted
economic models related to the interpretation of clinical
and quality of life benefits and the lack of sensitivity
analyses to show the impact of model assumptions [14].
With the advent of pCODR, which has embraced trans-
parent public reporting, other researchers in Canada have
begun studying pCODR reviews and have identified com-
mon issues with the time horizon chosen and post-pro-
gression survival estimates in models submitted by
manufacturers [11, 16, 17].
An Australian study [12] examined the common issues
identified in the submitted economic evidence for the
Australian Pharmaceutical Benefits Scheme. The com-
monly reported issues were related to the estimates of
comparative clinical efficacy, model structure, appropri-
ateness of the chosen comparator, and calculation errors.
A Dutch study reviewed 21 pharmacoeconomic evaluations
and found that the most common problems were related to
alignment of the study population with the registered drug
indication, type of economic analysis, and chosen time
horizon [13]. A study from France evaluated how uncer-
tainty was accounted for in cost-effectiveness analyses
submitted by manufacturers to the French National
Authority for Health and found that there was frequently a
lack of justification for plausible ranges in the sensitivity
analysis. As well, there were frequent omissions in reasons
for extrapolation of effects of the health technology beyond
the time horizon [18]. Finally, a study from the UK
reported on interviews with the National Institute for
Health and Care Excellence (NICE) Appraisal Committee
members who commonly expressed concerns with the
economic model structure and quality of clinical data [15].
Thus, while there have been some efforts to understand the
methodological issues faced by HTA agencies over the last
several years, the findings have typically been general and
based on a small number of reviews.
Some studies have made recommendations on improv-
ing and standardizing models in oncology [19–21]. One
study conducted a critical review of economic evaluations
pertaining to aromatase inhibitors in breast cancer and
found issues pertaining to time horizon and indirect
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comparisons [19]. The authors suggest in this area of
research a lifetime horizon should be taken with a sensi-
tivity analysis on this variable as well as distinguishing
indirect comparisons where actual data exists against a
common comparator and those that require additional
modeling. Another study examining published economic
models for adjuvant endocrine breast cancer treatments
found that there was variation in model structure and
parameterization and recommended improved guidance on
handling structural uncertainty [20].
To date, it also does not appear that potential associa-
tions between commonly cited issues and funding recom-
mendations have been explored in Canada or in other
jurisdictions worldwide. A few studies have examined the
relationship between economic evidence generally and
recommendations but have not examined specific
methodological issues [22, 23]. Knowing the types of
issues that economic reviewers encounter when evaluating
economic models can help improve models and avoid
commonly cited challenges, as well as inform priority areas
for future research to advance the field. As HTA continues
to play an essential role in decisions about drug funding,
and health system budgets face growing challenges in
adding new technologies, it is increasingly important to
engage in continuous learning and enhancement of the
methodological rigor of the analyses informing the health
technology review.
To provide further insight and specific guidance to those
who generate and use health economic evidence, the
objectives of this research were to (1) identify and examine
the main methodological issues reported by economic
reviewers, and (2) explore associations between reported
methodological issues and pCODR funding
recommendations.
2 Methods
Publicly available economic guidance report summaries
published on pCODR’s website between July 2011 (in-
ception) and June 2014 with a final funding recommen-
dation were independently examined by two study authors
(LM and JB). Drugs that were reviewed for multiple
indications at one time were included as distinct reviews in
this analysis. Both study authors abstracted issues raised
within the economic guidance reports and compared them
to reach consensus that all were captured. A list of cate-
gories for the main issues that emerged were developed
using common definitions for each category. Additionally,
both authors independently categorized each issue based on
their impressions of the economic reviewer’s necessary
actions to rectifying the issue or the issue’s implications on
the model results. The three approaches chosen were (1)
‘Addressed’ to improve the estimations (partially or com-
pletely), (2) ‘Explored’ to understand uncertainty, or (3)
left ‘Unresolved’. An Addressed issue was one in which
the reviewers made a model modification and revisions
were made to create what they felt was a better estimate of
the incremental cost-effectiveness ratio (ICER). An
Explored issue was one in which reviewers conducted a
sensitivity analysis around an estimate because they were
unsure of the best estimate. An Unresolved issue was one
in which reviewers could or did not address the issue. Two
authors (LM and JB) compared each drug’s categorizations
for any disagreements which were resolved through
discussion.
In addition to identifying the main issues, the final
funding recommendation for each indication was collected.
A review could have a negative, positive, or conditional
recommendation. A conditional recommendation often
meant that the drug was recommended for funding based
on clinical benefit, so long as the price of the drug could be
improved through procurement negotiations to achieve cost
effectiveness. To assess relationships between each main
issue categories and types of funding recommendation,
Fisher’s exact tests were conducted, with the existence of
each issue (yes or no) coded as a binary variable for each
drug/indication. Statistical analyses were conducted in
STATA 13 [24].
3 Results
A total of 34 economic guidance report summaries were
examined corresponding to 39 indications. The reviews
spanned a variety of disease sites and indications/settings.
The most common disease site was breast (n = 7) followed
by lung (n = 6). Other disease sites for which drugs were
being reviewed were prostate, leukemia, melanoma, gas-
trointestinal, lymphoma, myelofibrosis, myeloma, pancre-
atic, renal, and soft tissue sarcoma.
Among the issues identified in the included reviews,
nine categories of recurring problems were identified
(Fig. 1). The categories consisted of time horizon, model
structure, extrapolation, duration of benefit of treatment,
quality of clinical data, uncertainty with indirect compar-
ison, analytic errors, issues with utility estimates, and
costing assumptions.
Online resource 1 (see electronic supplementary mate-
rial) provides an overview of the pattern of issues found
and the economic reviewers’ actions for each individual
drug/indication reviewed. The economic reviewers most
frequently reported problems related to drug wastage and
other costing (59%) and time horizon (56%) issues, the
latter category indicative of concerns with overestimated
survival. The costing category included issues such as
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consideration of drug wastage, pricing compared with
existing therapies (e.g., where the comparator drug price is
confidential), healthcare resource use assumptions, and
impact of dose adjustments. Dose adjustments could have
large cost implications when tablets or capsules were
priced equally per unit regardless of strength; adjustments
requiring multiple tablets to make up the new dose could
double the cost per dose, which if not considered would
lead to underestimation of the expected incremental cost of
the new drug. The economic reviewer addressed the issues
pertaining to drug wastage and other costing in 70% (16/
23) of the instances, and the model permitted exploration
of the uncertainty for the remainder.
Time horizon, or overestimated survival, was identified
as a problem if the length of time chosen by the manu-
facturer was not deemed to be a realistic estimate of
maximum survival duration for the condition or supported
by the clinical data. For example, one report had a large
proportion of life expectancy gain in the extrapolated
portion of the model, and the economic reviewer suggested
a shorter time horizon, based on clinical input suggesting
that the majority of patients who initiated treatment would
likely die before the time assumed by the manufacturer. In
most instances, the reviewer shortened the time horizon to
align with more clinically plausible estimates of the max-
imum expected survival for the patient population under
study. However, in other instances, the time horizon was
shortened specifically to address model limitations. In these
instances, the survival and the incremental benefit pre-
dicted by the model as a result of extrapolation were
considered implausible, and in the absence of more direct
ways of addressing the cause of the bias, the time horizon
was shortened to mitigate accrual of long-term survival
gains that were unsubstantiated. The reviewer modified the
time horizon, addressing the issue in some way 95% (21/
22) of the time the issue was raised.
Issues with the submitted utility values were also iden-
tified (38%). Economic reviewers often identified alterna-
tive sources, values or assumptions for utility estimates. In
two instances, a reviewer expressed that utility estimates
that were more representative of the study population
would have been preferable. Where justification for dif-
ferences between treatment groups were weak, the
reviewer may have considered assuming equal utilities
among each treatment group, an approach that could still
be considered conservative without evidence about any
disutility patients may experience due to treatment. There
were also concerns with the methods of obtaining utility
values and the possible introduction of bias. Concerns
about utility values were addressed in 53% (8/15) of the
instances in which they were raised, and 27% (4/15) of the
time they were explored in a sensitivity analysis.
Concerns about duration of benefit, raised in about one
out of three reviews (33%), were also addressed in some
way the majority of the time (79%) (11/14). Duration of
benefit refers to the length of time in which treatment
effects are applied to the risks or hazard of events (i.e., in
reducing risks of progression or death). Problems with
duration of benefit were raised when the length of time the
drug was assumed to provide benefit was deemed
implausible, likely overestimating benefit. In addition to
explicit statements referring to duration of benefit of the
drug, this category also included references to post-pro-
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supported. For several submissions, reviewers described
the submitted model as assuming no distinction between a
patient’s risk of dying before tumor progression and a
patient’s risk of dying after tumor progression, implying
that patients continued to benefit from the drug even after
tumor progression occurred and the drug had been stopped
(i.e., a beneficial carry-over effect). In one instance, the
reviewer adjusted the model so that the drug did not have a
beneficial carry-over effect. In another submission, the
incremental survival benefits accrued post-progression with
the drug were excluded completely to explore the impact of
the implausible assumption.
Model structure, quality of clinical data, and statistical
problems with extrapolation were also identified as prob-
lems within the reports. Model structure issues were
identified if the economic reviewer indicated the structure
was inadequate for the purpose of the review. As a result of
concerns with the limitations of the model structure in one
review, the economic reviewer refrained from providing an
upper estimate of the ICER or sensitivity analyses. Model
structure issues were frequently raised as a result of use of
partitioned survival models, particularly as a result of
issues with extrapolating overall survival data. This often
occurred alongside concerns related to duration of benefit
(post-progression survival benefit) and time horizon. Fifty
percent (7/14) of the time, when a model structure issue
was raised, the reviewer could not resolve or explore the
implications of the issue.
Quality of clinical data issues, which were observed in
26% of the reviews, consisted of concerns around estimates
or assumptions that were not based on substantive evi-
dence, where studies had limited sample size, or were non-
comparative. Issues in this category could not be resolved
half of the time. It also encompassed issues related to
interpretation or application of data. For example, in one
review, the survival analysis excluded patients who expe-
rienced toxicity in the clinical study, which posed a risk of
bias in favor of the drug being reviewed. Similarly, sta-
tistical problems with the extrapolation method could not
be resolved 50% of the time it was raised. Issues were
categorized as extrapolation problems if the technical
aspects of survival curve fitting were not dealt with in the
model or dealt with incorrectly; for example, if the distri-
bution used did not appear to fit the clinical data suffi-
ciently or where pharmaceutical manufacturers did not
conduct or describe appropriate statistical tests for curve
fitting or lacked patient-level data. Concerns related to the
plausibility of extrapolation outcomes were encompassed
by the time horizon (overestimated survival) category, as
well as potentially through duration of benefit and model
structure categories.
Issues that were raised infrequently were analytic error
(10%) and uncertainty in indirect comparisons (21%). An
analytic error referred to an issue with the technical func-
tion of the model, or a major calculation or logic error that
called into question the face validity of the model. In one
submission, the progression-free survival function was not
estimated properly and led to illogical results (e.g., a sur-
vival of 103%). The economic reviewer was able to address
the analytic error in one out of the four submissions where
it was raised. Reviewers highlighted flawed indirect com-
parisons or uncertainty around the assumptions in the
conduct of an indirect comparison, which could only be
addressed in four out of the eight submissions where it was
raised. In one submission, the trials included in the indirect
comparison did not fulfill the assumptions about homo-
geneity, similarity, and consistency. However, based on
clinical input, the economic reviewer assumed equal effi-
cacy between drugs to counter this issue.
3.1 Issues and Funding Recommendations
Among the 39 indications, 54% had a conditional funding
recommendation, 26% had a positive recommendation, and
20% had a negative recommendation. A Fisher’s exact test
did not show a statistically significant association between
any main issue and the type of funding recommendation.
For time horizon and model structure, a trend was visually
observed (Figs. 2, 3), which suggests that there may be an
association between these variables and a funding recom-
mendation. For the reviews with a negative recommenda-
tion, there was an issue with time horizon 87% of the time,




























Fig. 2 Time horizon (overestimated survival) and funding recom-
mendation. Reviews with a negative recommendation had a time
horizon issue 87% of the time and those with a conditional
recommendation had a time horizon issue 57% of the time. The
vertical bars on each point estimate indicate the confidence interval
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recommendation, and only 30% of the time for positive
recommendations. A similar trend can be seen for model
structure. The rest of the issues did not demonstrate this
trend.
4 Discussion
While problems in economic submissions have been
explored previously [11–17], this is one of the first publi-
cations to look at the common issues identified by
pCODR’s economic reviewers.
Submitters are advised to consult the Canadian Agency
for Drugs and Technologies in Health guidelines for eco-
nomic evaluation. These guidelines provide an overview of
what should be considered in an economic evaluation.
However, there are limits to the amount of detail that can
be provided to address some of the methodological issues
that may be encountered. Importantly, there can be chal-
lenges in interpretation of the appropriateness of assump-
tions made when populating a model. Some of the issues
represent scenario analyses where the reviewers feel that a
particular scenario should be revised or explored to be in
line with current guidelines and provide a more appropriate
estimate. Other issues pertain to disagreements about what
the most appropriate estimate may be to meet the guide-
lines (e.g., time horizon). As well, some of the issues that
have arisen have not yet been fully addressed in the
guidelines, such as partitioned survival models or appro-
priate methods for extrapolation.
We found that the most commonly identified problems
involved main model inputs: the time horizon length,
costing, and utility estimates. These issues, however, could
be managed by the economic reviewers the majority of the
time, by making modifications to the model to address
alternative assumptions. Submitters should ensure these
parameters align with the clinical evidence, are clinically
plausible, and avoid introducing inappropriate bias towards
a particular treatment group. Validation of assumptions by
clinical experts may assist with this issue. Issues with
costing have been reported previously [12, 14], with
researchers stating that manufacturers often made costing
assumptions that favored the manufacturer’s products or
were very optimistic. We found the same costing problems;
pharmaceutical manufacturers often did not consider all
healthcare resource use or include the impact of drug
wastage or dose adjustments that might increase costs.
Though such issues are more easily handled through
modification of parameter values in models, the frequency
of occurrence likely impacts perceptions of objectivity
[25].
Problems around utility estimates have also been pre-
viously identified as common [12, 14]. In one study [14],
the reviewers disagreed with the way the quality-of-life
benefits were incorporated in the model as several of the
submissions assumed the adverse events arising from the
drug were lower than what the clinical evidence indicated.
In another study [12], it was expressed that utility estimates
were obtained from statistically non-significant or uncer-
tain clinical data. In our study, we found concerns with
elicitation methods as well as face validity when compared
with existing literature. Pharmaceutical manufacturers may
benefit from justifying their assumptions in light of existing
clinical evidence and also providing extensive sensitivity
analyses around utility estimates, including scenarios that
make alternate assumptions (e.g., where differences in
utility by treatment are assumed, also consider a scenario
assuming equal utilities for each treatment).
Previous research has called for the inclusion of suffi-
cient sensitivity analysis to show the impact of model
assumptions, particularly for costing and utility assump-
tions [14]. Although these issues still exist to some extent,
as mentioned above, economic reviewers could more easily
address these issues by conducting their own sensitivity
analyses. Previous calls to ensure access to fully transpar-
ent and executable models [14] have been met by pCODR
through their submission guidelines, which has facilitated
the review process by providing reviewers with the ability
to more rigorously interrogate a model. As a result, the
focus appears to have shifted towards more substantive






























Fig. 3 Model structure and funding recommendation. Reviews with a
negative recommendation had a model structure issue 62% of the time
and those with a conditional recommendation had a model structure
issue 38% of the time. The vertical bars on each point estimate
indicate the confidence interval
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Issues that were reported less frequently but posed more
substantive challenges for reviewers involved model
structure, extrapolation, and quality of clinical and com-
parative data informing the analysis. A model should be
validated for both internal and face validity before sub-
mission. This is in line with current economic guidelines
[9, 26, 27], but is particularly relevant for partitioned sur-
vival models, an increasingly common model structure
being applied to cancer care interventions, as this model
structure can easily produce biased estimates where
extrapolation is required to populate a substantial portion
of the model. While further research and additional
methodological guidance is required to inform the best
practice around use of partitioned survival models with
extrapolation, reasonable approaches could include sub-
stantive discussion surrounding the plausibility of long-
term outcomes arising from a partitioned survival model
and submitting alternative model structures using a
Markovian approach. Issues with overestimated clinical
benefits (time horizon), extrapolation, and quality of clin-
ical data echoed some of the findings from a Canadian
study that found there was a lack of validation of the
clinical evidence [14].
Our study found that economic reviewers reported
problems with extrapolation methods that often could not
be resolved, yielding overestimated survival. With oncol-
ogy drugs, it is common practice to adopt early into clinical
practice based on interim data [28], and in fact, there is
tremendous pressure from patients, patient groups, and
society to adopt new cancer therapies even earlier in their
life cycle. In potentially becoming sympathetic to unmet
clinical needs, regulatory data requirements have become
less demanding than funding review requirements and as a
result substantial extrapolation beyond trial data is often
necessary to form estimates of lifetime survival [28].
Researchers examining methods for extrapolation have
found that when extrapolating treatment benefits early in
the life cycle of the drug, the results may be inaccurate
depending on the assumptions used [29]. Some recom-
mendations have been to assess the sensitivity of the cost-
effectiveness analysis to different parametric forms of the
survival model as well as to take conservative approaches
to extrapolation [29, 30]. One study demonstrated the
importance of assessing the suitability of standard para-
metric models and suggested that if the standard distribu-
tions are not appropriate to represent the hazards, flexible
parametric survival functions should be used [31]. Another
study examining HTAs undertaken for NICE reported that
submitters often do not assess the appropriateness of the
extrapolated portion of the survival curve [32]. In light of
these findings, at minimum, thorough statistical evaluation
should be undertaken for model fitting, and the internal and
external validity should be explicitly assessed. An
algorithm has been proposed to guide analysts in selecting
the appropriate model [32]. While there may not be strict
formal methods to assess external validity, careful con-
sideration should be given to the implications of different
distributions on the assumed direction of the hazards
experienced by the cohort, and alternatives should be
explored when internally valid statistical approaches sug-
gest distributions that produce very long residual survival
without external clinical justification.
We found no statistically significant associations
between each main issue and funding recommendations,
though we observed patterns with time horizon and model
structure. The lack of statistical significance for these two
issues could be the result of a small sample size (n = 39
indications). As well, there are likely other factors even
within the economic domain that may play larger roles in
the formation of the final funding recommendation,
including clinical outcomes, uncertainty, and drug price
[33]. While some studies have examined the predictors of
type of funding recommendation, which included both
economic and clinical variables [22, 33–35], to the best of
our knowledge, no other studies have attempted to examine
the association between the issues the economic reviewers
have identified and the final funding recommendation. This
is an area for further research, including exploring causal
models to take the results beyond associations.
There are limitations to this study. First, the largest
limitation of a text-based analysis is that findings are lim-
ited to what was specifically mentioned in the reports.
Importantly, we were unable to assess whether the absence
of a description of an issue in the reports meant the absence
of an issue. This may have been rectified by consulting the
more detailed, unpublished technical reports or discussing
the results with the authors of the reports. However, we
only examined publicly available documents and did not
obtain additional information from the reviewers, the
committee, or the manufacturers to understand the impor-
tance of each issue or determine whether the issues
reported in the summary represented the full scope of
issues involved in the review. This limitation was evident
in the absence of descriptions related to early treatment
switching in clinical trials, which has been identified as an
ongoing challenge for oncology [36], but concerns related
to the implications of the methods used to adjust for cross-
over were not raised in any of the summary economic
guidance reports included in this study. It is also relevant
that the partitioned survival model structure may have been
commonly used but only raised as an issue in some reviews
and not in others, depending on the perceived appropri-
ateness of the approach by the reviewer to address the
specific circumstances of the review. Reviewers bring their
own philosophical, methodological background and
expertise. We are unable to address what beliefs reviewers
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bring to a review and cannot easily address or account for
their preferences or predispositions on how the review is
conducted or perceived. It is important to consider our
findings in light of this limitation. This factor may be part
of the review process in a way that impacts both the per-
ception of the submitted model and the revised estimates.
Second, this study relied on a small sample size of 34
economic guidance reports corresponding to 39 indica-
tions. However, we believe that much insight has been
gained into the common issues that economic reviewers
encounter when reviewing oncology drug submissions.
Lastly, other major factors considered in forming recom-
mendations, such as clinical evidence, alignment with
patient values, and adoption feasibility play important roles
in the funding recommendation. These factors were not
accounted for when conducting assessments of relation-
ships between economic issues and funding recommenda-
tions, but are important considerations that would be
relevant to future research in this area.
5 Conclusion
The types of issues that economic reviewers identify when
reviewing submissions are important for quality improve-
ment. In order to increase the quality of the submissions and
reviews, submitters, reviewers, and reimbursement review
agencies in Canada and elsewhere can benefit from a current
inventory of common issues from existing reviews to inform
and enhance guidance for conduct, reporting, and submis-
sion of economic evidence, interpretations of such guidance,
and review practices. We hope that the findings from this
study will inform improved economic submissions, support
consistency in economic reviews, and lead to advances in
methodological research, and that together these will sub-
sequently lead to better decision making.
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